United States

GSK receives FDA approval for MenHibrix

Monday, June 18, 2012 12:33 PM

The FDA has approved GlaxoSmithKline’s vaccine MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b in children aged six weeks through 18 months.

More... »

Saladax Biomedical names Harter president and CEO

Monday, June 18, 2012 11:35 AM

Saladax Biomedical, a Bethlehem, Penn.-based privately held company developing and commercializing novel diagnostic, has appointed Kevin M. Harter as president and chief executive officer.

More... »

Four more earn AAHRPP accreditation

Friday, June 15, 2012 01:54 PM

More... »

Altheus Therapeutics completes Zoenasa phase I trial in ulcerative colitis

Friday, June 15, 2012 11:34 AM

Altheus Therapeutics of Oklahoma City, Okla., has completed a two dose, double-blind, active-controlled phase I trial of the safety and tolerability of Zoenasa rectal suspension in adult patients with left-sided, or distal, ulcerative colitis.

More... »

Cell Therapeutics appoints Benner as new CMO

Friday, June 15, 2012 11:11 AM

Cell Therapeutics, a Seattle-based company focused on translating science into novel cancer therapies, has appointed former OncoMed Pharmaceuticals executive, Steven E. Benner, M.D., M.H.S., as its executive vice president and chief medical officer.

More... »

Particle Sciences expands cGMP capabilities with thin films

Friday, June 15, 2012 09:09 AM

More... »

Over 90 CROs launch BioResearch Central collaboration

Thursday, June 14, 2012 12:48 PM

More than 90 CROs and related service providers in the Kansas City area have banded together to form the BioResearch Central, a collaboration dedicated to accelerating the development of new medicines and medical devices to improve the health and well-being of patients worldwide.

More... »

Seventh Sense Biosystems appoints Weisman as president and CEO

Thursday, June 14, 2012 12:21 PM

Seventh Sense Biosystems, a Cambridge, Mass.-based privately-held medical device company developing the novel Touch Activated Phlebotomy (TAP) painless blood sampling system, has appointed Howard Weisman as president, CEO and board member.  

More... »

Selexys Pharmaceuticals concludes phase I study in sickle cell disease

Thursday, June 14, 2012 11:54 AM

Selexys Pharmaceuticals, a privately held biopharmaceutical company based in Oklahoma City, Okla., has completed a phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

More... »

Rhythm raises $25M in Series B financing for diabetes and obesity

Thursday, June 14, 2012 09:14 AM

Rhythm, a biotech based in Boston, Mass., has raised $25 million in a Series B financing round, bringing the total capital raised to $65 million.

More... »